In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Prognostic value of dipyridamole stress CMR in patients with known or suspected coronary artery disease: a long term follow-up study

Session Abstract session 1: value of CMR stress perfusion: latest evidence

Speaker Alessia Pepe

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Stress CMR
  • Session type : Abstract Session
  • FP Number : 268

Authors : A Pepe (Pisa,IT), C Nugara (Palermo,IT), M Vaccaro (Catania,IT), C Grigoratos (Pisa,IT), G Todiere (Pisa,IT), A Barison (Pisa,IT), D De Marchi (Pisa,IT), G Novo (Palermo,IT), G Aquaro (Pisa,IT), A Meloni (Pisa,IT)

A Pepe1 , C Nugara2 , M Vaccaro3 , C Grigoratos1 , G Todiere1 , A Barison1 , D De Marchi1 , G Novo2 , G Aquaro1 , A Meloni1 , 1Fondazione Toscana Gabriele Monasterio - Pisa - Italy , 2University of Palermo - Palermo - Italy , 3University of Catania - Catania - Italy ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii197

Background: Dipyridamole stress CMR provides detailed information on the key phases (perfusion and wall motion) of the ischemic cascade. Although the diagnostic value of stress CMR has been assessed, further studies are needed to evaluate its prognostic role at long-term, specifically using dipyridamole where no data are available to our knowledge. So, the aim of this study was to determine the long-term prognostic value of dipyridamole stress-CMR in patients with known or suspected coronary artery disease (CAD).

Methods: Two hundred and forty-six consecutive patients (61 females, main age 61.96±10.05 years) who underwent dipyridamole stress-CMR in a high volume CMR Laboratory were considered. Abnormal wall motion at rest and after dipyridamole, perfusion at stress and at rest, and late gadolinium enhancement (LGE) were analysed.
End-points were "major non-fatal cardiac events" (ventricular arrhythmias, coronary syndromes, heart failure hospitalization) and cardiac death.

Results: Mean left ventricular ejection fraction was 60.45±13.47% and myocardial fibrosis was detected in 95 (38.6%) patients.
An abnormal stress CMR was found in 65 (26.4%) patients; 39 patients had a reversible stress perfusion defect in at least one myocardial segment and 26 a reversible stress perfusion defect plus worsening of stress wall motion in comparison with rest.
During a median follow up of 60.59 months (IQ range 41.98 months),  69 patients (28.0%) experienced major nonfatal cardiac events. LGE, reversible perfusion deficit, age, diabetes and family history were univariate prognosticators. In the multivariate analysis the independent predictive factors were reversible  perfusion deficit (hazard ratio-HR=2.21, P=0.001) and diabetes (HR=2.21, P=0.003).
Ten patients died during follow-up and reversible motion abnormality and LGE were univariate prognosticators. At multivariate analysis, LGE remained a significant prognosticator (HR=10.83, P=0.026), after adjusting for age and diabetes.
When the composite end-point (cardiac events + death) was considered, both myocardial fibrosis and reversible perfusion deficit resulted to be significant univariate prognosticators, in addition to age, diabetes and family history. At multivariate analysis the independent predictive factors were reversible  perfusion deficit (HR=2.26, P<0.0001) and diabetes (HR=2.59, P<0.0001) (Figure 1).

Conclusions: Reversible perfusion deficit and diabetes identify patients at high risk of fatal and non fatal cardiac events. LGE is a strong predictor for death in patients with known or suspected CAD.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are